AIxURO Technology Integration AIxMed's AIxURO ™ solution is specifically developed to assist in the analysis of non-invasive ...

The global AI-Powered Pathology Market is projected to grow significantly in the coming years. It was valued at USD 184 Million in 2023 and is forecast to reach USD 382 Million by 2030, representing a ...

Altamont Software, a provider of enterprise medical connectivity solutions, announces the availability of our Dynamic Content engine within Passport SR. This feature provides the ability to calculate ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025 ...

Tier 1 aberrations, which are classified as those having well-established prognostic, diagnostic, or therapeutic relevance according to guidelines set by medical societies such as WHO, NCCN and ICC, ...

Q3 2025 Management View CEO Ming Hsieh reported "sustained momentum in the business" for the third quarter, highlighting ...

Looking to boost your income without leaving home? Check out these 11 remote jobs that offer flexibility, stability, and pay ...

An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more ...

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

Trained on 500,000 pathology slides, the AI predicts cancer type, treatment response, and survival with over 95% accuracy ...

Development in artificial intelligence has paved the path for the integration of computational pathology in clinical workflow, improving the accuracy and reducing the workload for medical ...

Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline ...